Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives

doi:10.3748/wjg.v17.i26.3075

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 26

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3035)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

261

HTML

2235

Figures (1-1)

212

Tables (1-3)

327

Sum=3035

Jul 14, 2011 (publication date) through Jan 18, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jul 14, 2011; 17(26): 3075-3081
Published online Jul 14, 2011. doi: 10.3748/wjg.v17.i26.3075

Full Size Figure Download Figure

Figure 1 Dynamic gadolinium-enhanced magnetic resonance imaging (MRI; T1, T2 weighting), in a 67 year old patient with hepatocellular carcinoma evolved from liver cirrhosis due to hemochromatosis (A) before initiation of anti-angiogenic therapy and (B) after 70 d or three cycles of transarterial chemoembolization and continuous administration of sorafenib, respectively. Patient showed partial response according to RECIST criteria. Serum alfa-fetoprotein level decreased from 276 to 115 ng/mL.

Citation: Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081
URL: https://www.wjgnet.com/1007-9327/full/v17/i26/3075.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i26.3075